November 5, 2015
Categories: Digital and Social Media
Patients are at the forefront of everything we do in the healthcare industry, making the notion of patient-centricity a worthwhile and noble concept. When it comes to social media, however, pharma needs to learn how to put the person before the patient. Chris Iafolla is the head of the Digital & Social Strategy practice at inVentiv Health Public Relations Group. Click here to read this article in full in O’Dwyer’s November 2015 issue on page 35.
By now, you have probably heard that an Instagram post by Kim Kardashian, promoting morning sickness treatment Diclegis, has landed drug maker Duchesnay in hot water with the FDA. The company received a warning letter from the FDA for an Instagram post the agency says: “entirely omits all risk information.” The post, which appeared on Instagram with a picture of Kim holding a bottle of the treatment, is embedded below. “OMG. Have you heard about this? As you guys know my #morningsickness has been pretty bad. I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor. He prescribed me #Diclegis, and I felt a lot better and most importantly, it’s been studied and there was no increased risk to the baby. I’m so excited and happy with my results that I’m partnering with Duchesnay USA to raise awareness about treating morning sickness. If you have morning sickness, be safe and sure to ask your doctor about the pill with the pregnant woman on it and find out more www.diclegis.com; www.DiclegisImportantSafetyInfo.com.” When news of the warning letter began to spread, it sparked a narrative focused on the perils of social media forContinue Reading